EODData

MEMBERSHIP REGISTER LOG IN

AMEX, TOVX: Theriva Biologics Inc

07 Nov 25 15:59
LAST:

0.2779

CHANGE:
 0.00		OPEN:
0.2690		HIGH:
0.2783		ASK:
0.0000		VOLUME:
1.37M
CHG(%):
1.43		PREV:
0.2733		LOW:
0.2594		BID:
0.0000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
07 Nov 250.27110.27830.26220.27721.54M
06 Nov 250.29000.29590.26270.27335.11M
05 Nov 250.30060.30060.29000.29612.09M
04 Nov 250.30000.30440.29000.29732.71M
03 Nov 250.31500.33200.30030.32503.9M
31 Oct 250.31840.31990.30030.31243.58M
30 Oct 250.29350.35280.29070.32409.24M
29 Oct 250.32000.32500.29800.310010.32M
28 Oct 250.31160.35610.31160.331313.88M
27 Oct 250.33950.34500.30200.327617.03M

COMPANY PROFILE

Name:Theriva Biologics Inc
About:Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. It has collaboration agreements with The University of Texas at Austin, Catalan Institute of Oncology, Fundació Privada Institut d'Investigacio Biomedica de Bellvitge, Saint Joan De Déu, and Massachusetts General Hospital, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
Sector:Healthcare
Industry:Biotechnology
Address:9605 Medical Center Drive, Rockville, MD, United States, 20850
Website:https://therivabio.com
CIK:0000894158
ISIN:US87164U5083
FIGI:BBG000BV6QX8

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-0.02 
Forward P/E:-0.02 
PEG Ratio:0.00 
Price to Book:0.28 
Return on Assets:-0.42 
Return on Equity:-1.54 
EPS Ratio:-4.22 
Shares:9.6M 
Market Cap:2.67M 

TECHNICAL INDICATORS

MA5:0.295.7%
MA10:0.3110.6%
MA20:0.3630.7%
MA50:0.3942.0%
MA100:0.4251.1%
MA200:0.75168.3%
STO9:4.71 
STO14:0.68 
RSI14:37.88 
WPR14:-94.56 
MTM14:-0.02
ROC14:-0.08 
ATR:0.07 
Week High:0.3319.5%
Week Low:0.266.0%
Month High:0.86210.6%
Month Low:0.26168.3%
Year High:2.22698.8%
Year Low:0.266.0%
Volatility:148.01 

RECENT SPLITS

Date Ratio
26 Aug 20241-25
25 Jul 20221-10
13 Aug 20181-35
25 Apr 20071-3

RECENT DIVIDENDS

Date Amount
25 Apr 2022$375.00
16 Apr 2021$125.00
24 Jul 2020$125.00